{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:18:42Z","timestamp":1779884322914,"version":"3.53.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["IUMS\/SHMIS_97-3-37-12819"],"award-info":[{"award-number":["IUMS\/SHMIS_97-3-37-12819"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Heart failure (HF) is an unusual heart function that causes reduction in cardiac or pulmonary output. Cardiac resynchronization therapy (CRT) is a mechanical device that helps to recover ventricular dysfunction by pacing the ventricles. This study planned to systematically review cost-effectiveness of CRT combined with an implantable cardioverter-defibrillator (ICD) versus ICD in patients with HF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used five databases (NHS Economic Evaluation Database, Cochrane Library, Medline, PubMed, and Scopus) to systematically reviewed studies published in the English language on the cost-effectiveness of CRT with defibrillator (CRT-D) Vs. ICD in patients with HF over 2000 to 2020. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist was applied to assess the quality of the selected studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Five studies reporting the cost-effectiveness of CRT-D vs ICD were finally identified. The results revealed that time horizon, direct medical costs, type of model, discount rate, and sensitivity analysis obviously mentioned in almost all studies. All studies used quality-adjusted life years (QALYs) as an effectiveness measurement. The highest and the lowest Incremental cost-effectiveness ratio (ICER) were reported in the USA ($138,649per QALY) and the UK ($41,787per QALY), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Result of the study showed that CRT-D compared to ICD alone was the most cost-effective treatment in patients with HF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12962-021-00285-5","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T08:03:04Z","timestamp":1621584184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness of cardiac resynchronization therapy plus an implantable cardioverter-defibrillator in patients with heart failure: a systematic review"],"prefix":"10.1186","volume":"19","author":[{"given":"Abedin","family":"Teimourizad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Rezapour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Sadeghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masih","family":"Tajdini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"285_CR1","unstructured":"World Health Organization (WHO): The Global Burden of Disease 2004 Update. 2008. Geneva, Switzerland: World Health Organization. http:\/\/apps.who.int\/ghodata\/"},{"issue":"3","key":"285_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ejheart.2005.01.001","volume":"7","author":"S Stewart","year":"2005","unstructured":"Stewart S. Financial aspects of heart failure programs of care. Eur J Heart Fail. 2005;7(3):423\u20138.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"285_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccl.2013.09.009","volume":"32","author":"L Liu","year":"2014","unstructured":"Liu L, Eisen HJ. Epidemiology of heart failure and scope of the problem. Cardiol Clin. 2014;32(1):1\u20138.","journal-title":"Cardiol Clin"},{"issue":"4","key":"285_CR4","first-page":"363","volume":"33","author":"J Lopez-Sendon","year":"2011","unstructured":"Lopez-Sendon J. The heart failure epidemic. Medicographia. 2011;33(4):363\u20139.","journal-title":"Medicographia"},{"issue":"3","key":"285_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1388-9842(99)00032-X","volume":"1","author":"JG Cleland","year":"1999","unstructured":"Cleland JG, et al. Is the prognosis of heart failure improving? Eur J Heart Fail. 1999;1(3):229\u201341.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"285_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/heart.83.5.505","volume":"83","author":"MR Cowie","year":"2000","unstructured":"Cowie MR, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000;83(5):505\u201310.","journal-title":"Heart"},{"issue":"1 Pt 1","key":"285_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0002-8703(99)70251-6","volume":"138","author":"FA McAlister","year":"1999","unstructured":"McAlister FA, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J. 1999;138(1 Pt 1):87\u201394.","journal-title":"Am Heart J"},{"key":"285_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.csbj.2016.11.001","volume":"15","author":"EE Tripoliti","year":"2017","unstructured":"Tripoliti EE, et al. Heart failure: diagnosis, severity estimation and prediction of adverse events through machine learning techniques. Comput Struct Biotechnol J. 2017;15:26\u201347.","journal-title":"Comput Struct Biotechnol J"},{"issue":"3","key":"285_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","volume":"6","author":"PA Heidenreich","year":"2013","unstructured":"Heidenreich PA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606\u201319.","journal-title":"Circ Heart Fail"},{"issue":"3","key":"285_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0895-4356(99)00135-3","volume":"53","author":"W Kannel","year":"2000","unstructured":"Kannel W. Vital epidemiologic clues in heart failure. J Clin Epidemiol. 2000;53(3):229\u201335.","journal-title":"J Clin Epidemiol"},{"issue":"2\u20133","key":"285_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0167-5273(01)00497-1","volume":"80","author":"GF Mendez","year":"2001","unstructured":"Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries: a review of the literature. Int J Cardiol. 2001;80(2\u20133):213\u20139.","journal-title":"Int J Cardiol"},{"issue":"5","key":"285_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.7326\/0003-4819-141-5-200409070-00102","volume":"141","author":"G Nichol","year":"2004","unstructured":"Nichol G, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med. 2004;141(5):343\u201351.","journal-title":"Ann Intern Med"},{"issue":"24","key":"285_CR13","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1093\/eurheartj\/ehi662","volume":"26","author":"MJ Calvert","year":"2005","unstructured":"Calvert MJ, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J. 2005;26(24):2681\u20138.","journal-title":"Eur Heart J"},{"issue":"12","key":"285_CR14","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.jacc.2005.08.033","volume":"46","author":"AM Feldman","year":"2005","unstructured":"Feldman AM, et al. Cost effectiveness of cardiac resynchronization therapy in the comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) trial. J Am Coll Cardiol. 2005;46(12):2311\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"285_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/eurheartj\/ehl382","volume":"28","author":"G Yao","year":"2007","unstructured":"Yao G, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28(1):42\u201351.","journal-title":"Eur Heart J"},{"key":"285_CR16","unstructured":"National Institute for Health and Care Excellence. Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure. 2014. http:\/\/guidance.nice.org.uk\/ta314"},{"key":"285_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000276","author":"M Ney","year":"2011","unstructured":"Ney M, et al. Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model. BMJ Open. 2011. https:\/\/doi.org\/10.1136\/bmjopen-2011-000276.","journal-title":"BMJ Open"},{"issue":"2","key":"285_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1017\/S0266462313000160","volume":"29","author":"D Husereau","year":"2013","unstructured":"Husereau D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Int J Technol Assess Health Care. 2013;29(2):117\u201322.","journal-title":"Int J Technol Assess Health Care"},{"issue":"5","key":"285_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10741-018-9710-3","volume":"23","author":"A Jafari","year":"2018","unstructured":"Jafari A, Rezapour A, Hajahmadi M. Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review. Heart Fail Rev. 2018;23(5):693\u2013700.","journal-title":"Heart Fail Rev"},{"issue":"6","key":"285_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M14-1804","volume":"163","author":"CY Woo","year":"2015","unstructured":"Woo CY, et al. Cost-effectiveness of adding cardiac resynchronization therapy to an implantable cardioverter-defibrillator among patients with mild heart failure. Ann Intern Med. 2015;163(6):417\u201326.","journal-title":"Ann Intern Med"},{"issue":"1","key":"285_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1540-8167.2012.02413.x","volume":"24","author":"K Noyes","year":"2013","unstructured":"Noyes K, et al. Cost effectiveness of cardiac resynchronization for the prevention of heart failure. J Cardiovasc Electrophysiol. 2013;24(1):66.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"21","key":"285_CR22","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1136\/heartjnl-2015-308883","volume":"102","author":"S Mealing","year":"2016","unstructured":"Mealing S, et al. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. Heart. 2016;102(21):1742\u20139.","journal-title":"Heart"},{"issue":"3","key":"285_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ijcard.2011.06.046","volume":"163","author":"EG Bertoldi","year":"2013","unstructured":"Bertoldi EG, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country\u2019s public health system. Int J Cardiol. 2013;163(3):309\u201315.","journal-title":"Int J Cardiol"},{"key":"285_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1746316","author":"D Shah","year":"2020","unstructured":"Shah D, et al. Cost-effectiveness analysis of implantable cardiac devices in patients with systolic heart failure: A US perspective using real world data. J Med Econ. 2020. https:\/\/doi.org\/10.1080\/13696998.2020.1746316.","journal-title":"J Med Econ"},{"issue":"11","key":"285_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2165\/11313670-000000000-00000","volume":"27","author":"F Augustovski","year":"2009","unstructured":"Augustovski F, et al. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacoeconomics. 2009;27(11):919\u201329.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"285_CR26","first-page":"112","volume":"18","author":"RM Baltussen","year":"2002","unstructured":"Baltussen RM, et al. Uncertainty in cost-effectiveness analysis: probabilistic uncertainty analysis and stochastic league tables. Int J Technol Assess Health Care. 2002;18(1):112\u20139.","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"285_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1017\/S0266462305050221","volume":"21","author":"M Drummond","year":"2005","unstructured":"Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care. 2005;21(2):165\u201371.","journal-title":"Int J Technol Assess Health Care"},{"issue":"7","key":"285_CR28","doi-asserted-by":"publisher","first-page":"A441","DOI":"10.1016\/j.jval.2014.08.1160","volume":"17","author":"S Ghabri","year":"2014","unstructured":"Ghabri S, et al. Exploring uncertainty in economic evaluation of medicines: a review of the first manufacturers\u2019 submissions to the French National Authority For Health (Has). Value Health. 2014;17(7):A441\u20132.","journal-title":"Value Health"},{"issue":"6","key":"285_CR29","first-page":"59","volume":"91","author":"S Limwattananon","year":"2011","unstructured":"Limwattananon S. Handling uncertainty of the economic evaluation result: sensitivity analysis. J Med Assoc Thai. 2011;91(6):59.","journal-title":"J Med Assoc Thai"},{"issue":"4","key":"285_CR30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1540-8159.2010.02703.x","volume":"33","author":"H Ghanbari","year":"2010","unstructured":"Ghanbari H, et al. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol. 2010;33(4):400\u20136.","journal-title":"Pacing Clin Electrophysiol"},{"key":"285_CR31","unstructured":"Rickard J, et al. Use of cardiac resynchronization therapy in the medicare population. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015."},{"issue":"3","key":"285_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1161\/CIRCULATIONAHA.115.018830","volume":"133","author":"C Lindvall","year":"2016","unstructured":"Lindvall C, et al. National trends in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator. Circulation. 2016;133(3):273\u201381.","journal-title":"Circulation"},{"key":"285_CR33","doi-asserted-by":"publisher","DOI":"10.17795\/ijcp-4061","author":"N Hatam","year":"2015","unstructured":"Hatam N, et al. Cost-utility analysis of IEV drug regimen versus ESHAP drug regimen for the patients with relapsed and refractory hodgkin and non-hodgkin\u2019s lymphoma in Iran. Iranian journal of cancer prevention. 2015. https:\/\/doi.org\/10.17795\/ijcp-4061.","journal-title":"Iranian journal of cancer prevention"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-021-00285-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-021-00285-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-021-00285-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T08:05:02Z","timestamp":1621584302000},"score":1,"resource":{"primary":{"URL":"https:\/\/resource-allocation.biomedcentral.com\/articles\/10.1186\/s12962-021-00285-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1186\/s12962-021-00285-5","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"9 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}